Literature DB >> 11526486

Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis.

S Kanzler1, E Meyer, A W Lohse, P Schirmacher, J Henninger, P R Galle, M Blessing.   

Abstract

The potent growth-inhibitory activity of cytokines of the transforming growth factor-beta (TGF-beta) superfamily and their widespread expression in epithelia suggest that they may play an important role in the maintenance of epithelial homeostasis. To analyse TGF-beta mediated tumor suppressor activity in the liver, we generated transgenic mice overexpressing a dominant negative type II TGF-beta receptor in hepatocytes under control of the regulatory elements of the human C-reactive protein gene promoter. Transgenic animals exhibited constitutive and liver-specific transgene expression. The functional inactivation of the TGF-beta signaling pathway in transgenic hepatocytes was shown by reduced TGF-beta induced inhibition of DNA synthesis in primary hepatocyte cultures. Liver morphology and spontaneous tumorigenesis were unchanged in transgenic mice suggesting that interruption of the signaling of all three isoforms of TGF-beta in hepatocytes does not disturb tissue homeostasis in the liver under physiological conditions. However, following initiation with the carcinogen diethylnitrosamine and tumor-promotion with phenobarbital transgenic mice exhibited a moderate albeit significant increase in the incidence, size and multiplicity of both preneoplastic tissue lesions in the liver and of hepatocellular carcinomas. These results give in vivo evidence for a tumor suppressor activity of the endogenous TGF-beta system in the liver during chemical hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11526486     DOI: 10.1038/sj.onc.1204544

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

1.  Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis.

Authors:  Ashley M Lakner; Nury M Steuerwald; Tracy L Walling; Sriparna Ghosh; Ting Li; Iain H McKillop; Mark W Russo; Herbert L Bonkovsky; Laura W Schrum
Journal:  Hepatology       Date:  2012-06-18       Impact factor: 17.425

2.  Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2.

Authors:  Yu-An Yang; Gen-Mu Zhang; Lionel Feigenbaum; Ying E Zhang
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

Review 3.  Genetics of hepatocellular carcinoma.

Authors:  Andreas Teufel; Frank Staib; Stephan Kanzler; Arndt Weinmann; Henning Schulze-Bergkamen; Peter-R Galle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

Review 4.  Molecular mechanisms of head and neck cancer.

Authors:  Amit M Deshpande; David T Wong
Journal:  Expert Rev Anticancer Ther       Date:  2008-05       Impact factor: 4.512

5.  Cytosolic phospholipase A2alpha and peroxisome proliferator-activated receptor gamma signaling pathway counteracts transforming growth factor beta-mediated inhibition of primary and transformed hepatocyte growth.

Authors:  Chang Han; William C Bowen; Guiying Li; Anthony J Demetris; George K Michalopoulos; Tong Wu
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

6.  Intersecting pathways in inflammation and cancer: Hepatocellular carcinoma as a paradigm.

Authors:  Philip Y Wai; Paul C Kuo
Journal:  World J Clin Oncol       Date:  2012-02-10

Review 7.  The TGFBeta pathway as a therapeutic target in cancer.

Authors:  J Seoane
Journal:  Clin Transl Oncol       Date:  2008-01       Impact factor: 3.405

8.  Expression of transforming growth factor β1 promotes cholangiocarcinoma development and progression.

Authors:  Chiung-Kuei Huang; Arihiro Aihara; Yoshifumi Iwagami; Tunan Yu; Rolf Carlson; Hironori Koga; Miran Kim; Jing Zou; Sarah Casulli; Jack R Wands
Journal:  Cancer Lett       Date:  2016-06-27       Impact factor: 8.679

9.  The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.

Authors:  L Lin; R Amin; G I Gallicano; E Glasgow; W Jogunoori; J M Jessup; M Zasloff; J L Marshall; K Shetty; L Johnson; L Mishra; A R He
Journal:  Oncogene       Date:  2009-01-12       Impact factor: 9.867

10.  Liver stem cells and tgf-Beta in hepatic carcinogenesis.

Authors:  Rupen Amin; Lopa Mishra
Journal:  Gastrointest Cancer Res       Date:  2008-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.